On September 17, Twist Bioscience Corp rose 6.4% in regular trading, trading at $152.895 per share with turnover of $25.83 million, extending a multi-session rally driven by a series of positive catalysts.
On the news front, the company announced a collaboration with Lilly TuneLab, Eli Lilly's AI/ML drug discovery platform, to provide antibody characterization data services. This partnership further solidifies Twist's positioning at the intersection of synthetic biology and AI-driven drug development. Additionally, at the Baird Global Healthcare Conference, CEO disclosed that fiscal Q4 revenue is expected to reach approximately $124 million, representing roughly 25% year-over-year growth and exceeding the FactSet consensus estimate of $117.4 million, marking a potential 15th consecutive quarter of revenue growth. The company also revealed that AI pharma-related orders have reached $50 million and are projected to double to $100 million next year. This momentum builds on the August announcement that Anthropic selected Twist as an independent evaluator for a multi-arm AI protein design project, which drove a 17% single-day surge. Shares have gained over 50% since August.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments